Praxis Precision surges on positive ulixacaltamide data for essential tremor, but tolerability limits impact. Explore PRAX's ...

Success by nearly all measures with Praxis Precision Medicines Inc.’s essential tremor phase III candidate, ulixacaltamide, drove the company’s stock up significantly and provided solid data for an ...

Praxis Precision Medicines said patients with a condition that causes uncontrollable shaking saw improvement using its ...

Shares of biopharmaceutical company Praxis Precision Medicines Inc. soared Thursday, boosted by the successful trial of a new ...

Shares of Praxis Precision Medicines more than tripled Thursday, peaking at $200 apiece, after the company disclosed positive ...

Praxis Precision Medicines’ commitment to forging ahead with ulixacaltamide in essential tremor (ET) has paid off. | The ...

Shares of the Boston company, which closed Wednesday at $57.35, were recently up 109% to $119.83. Praxis said the two Phase 3 studies of ulixacaltamide met their primary endpoints in essential tremor, ...

Sound waves at frequencies above the threshold for human hearing are routinely used in medical care. Also known as ultrasound ...

A powerful 7.4-magnitude earthquake struck off the southern coast of the Philippines on October 10, triggering tsunami warnings across the region, including Indonesia and Palau. The quake hit in the ...

After having her head shaved by nurses at Novant Health Mint Hill Medical Center, patient Catherine Klie's right hand shook ...

Locals in coastal areas were ordered to evacuate immediately and see higher ground. Follow Newsweek for live updates.

AbbVie Inc. (NYSE:ABBV) on Monday shared topline results from the Phase 2 ELATE trial evaluating onabotulinumtoxinA (BOTOX) compared to placebo for upper limb essential tremor. Upper limb essential ...